Charles River Laboratories International (CRL) Equity Average (2010 - 2025)

Charles River Laboratories International (CRL) has reported Equity Average for 16 consecutive years, with $3.3 billion the latest figure, recorded in Q4 2025.

• In Q4 2025, Equity Average fell 9.29% year-over-year to $3.3 billion; the TTM figure through Dec 2025 stood at $3.3 billion (down 9.29% YoY), while the FY2025 annual figure was $3.3 billion, down 6.12% from the prior year.
• Equity Average came in at $3.3 billion for Q4 2025 at Charles River Laboratories International, down from $3.4 billion in the prior quarter.
• The five-year high for Equity Average was $3.8 billion in Q3 2024, with the low at $2.2 billion in Q1 2021.
• Average Equity Average over 5 years is $3.0 billion, with a median of $3.2 billion recorded in 2023.
• Across the five-year window, Equity Average surged 32.21% in 2021 and declined 11.03% in 2025, its largest moves.
• Year by year, Equity Average stood at $2.5 billion in 2021, then increased by 12.93% to $2.8 billion in 2022, then advanced by 23.14% to $3.5 billion in 2023, then climbed by 4.85% to $3.6 billion in 2024, then declined by 9.29% to $3.3 billion in 2025.
• According to Business Quant data, Equity Average over the past three periods registered $3.3 billion, $3.4 billion, and $3.3 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.